Related Experiment Video
Updated: Jul 30, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Valsartan and retinal endothelial function in elderly hypertensive patients
Sebastian Oehmer1, Joanna Harazny, Christian Delles
1Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany.
Blood Pressure
|July 26, 2006
Summary
Short-term valsartan treatment did not improve retinal endothelial function in elderly hypertensive patients, despite lowering blood pressure. Retinal blood flow responses were unchanged, but LDL cholesterol levels influenced capillary flow changes.
Area of Science:
- Cardiovascular Research
- Ophthalmology
- Pharmacology
Background:
- Essential hypertension affects elderly individuals, potentially impacting retinal microvasculature.
- Endothelial dysfunction is a key factor in hypertensive complications.
- Angiotensin II receptor blockers (ARBs) are used to manage hypertension.
Purpose of the Study:
- To evaluate the effect of short-term valsartan treatment on retinal endothelial function in elderly hypertensive patients.
- To assess changes in central retinal artery perfusion and retinal capillary flow.
- To investigate the influence of low-density lipoprotein (LDL) cholesterol on treatment response.
Main Methods:
- Open-label study involving 20 elderly male patients with mild to moderate essential hypertension.
- Treatment with valsartan (80-160 mg/day) for 8 days.
- Assessment of central retinal artery perfusion (Doppler sonography) and retinal capillary flow (laser Doppler flowmetry) before and after treatment, including response to NG-monomethyl-L-arginine (L-NMMA).
Main Results:
- Valsartan significantly reduced blood pressure but did not alter central retinal artery perfusion at rest or during stimulation.
- Retinal capillary flow at rest and after L-NMMA infusion remained unchanged.
- A subgroup analysis indicated that changes in capillary flow response to L-NMMA were dependent on LDL cholesterol levels.
Conclusions:
- Short-term valsartan therapy does not improve retinal endothelial function in elderly hypertensive patients.
- The impact of valsartan on retinal microvascular function may be influenced by baseline LDL cholesterol levels.
- Further research is needed to explore long-term effects and specific patient subgroups.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...